[November 24, 2014] |
|
CureDuchenne Media Statement Regarding BioMarin's and Prosensa Holding N.V.'s Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare Disease Portfolio
NEWPORT BEACH, Calif. --(Business Wire)--
CureDuchenne is encouraged about BioMarin Pharmaceutical's acquisition
of Prosensa and their commitment to continue the development of drugs
for Duchenne muscular dystrophy. BioMarin has a deep understanding of
the orphan rare disease space, experience working with regulatory
authorities worldwide, and a successful record of getting drugs
approved. CureDuchenne supports all research efforts that further the
development of treatment options for boys with Duchenne.
CureDuchenne has played a critical role in helping to fund Prosensa for
more tha 10 years that has helped bring drisapersen to its current
stage of development. Drisapersen is currently under a rolling review as
part of the New Drug Application process. CureDuchenne has also funded
Prosensa's other exon skipping compounds that are under development.
"CureDuchenne has been a dedicated supporter of Prosensa since our
company's inception," said Hans Schikan, Chief Executive Officer of
Prosensa. "CureDuchenne's funding came at critical times during our drug
development process and their longtime commitment has been of enormous
value to the company. The transaction with BioMarin will enhance our
mission by bringing innovative therapies to patients across the world as
quickly as possible."
"Our commitment to finding treatments for Duchenne is unwavering," said
Debra Miller, Founder and CEO of CureDuchenne. "We have been there every
step of the way for Prosensa and are encouraged that BioMarin will
continue this effort that will hopefully lead to approval of drisapersen
and a pipeline of other follow on exons."
[ Back To TMCnet.com's Homepage ]
|